Latest news

• GSK’s shingles vaccine Shingrix claims US approval

  GSK’ s shingles vaccine Shingrix claims US approval. Becomes first alternative to Merck &Co’s Zostavax. ... The FDA has approved Shingrix for the prevention of shingles in adults aged 50 years and older, and it becomes the first alternative to Merck

• GSK's Shingrix sails through FDA advisory committee

  It is increasingly common with advancing age. GSK is hoping that increased efficacy means it will be favoured ahead of Zostavax and also drive up vaccination rates against shingles, which remain ... In June, the company reported the results of a trial

• GSK makes case for revaccination with Shingrix

  The results of the Zoster-048 study met its primary objective of showing that people who had received the currently-approved vaccine - Merck &Co's Zostavax - at least five years previously ... after clinical data demonstrated the drug's greater efficacy

• GSK files shingles vaccine Shingrix in Europe

  GSK files shingles vaccine Shingrix in Europe. Blockbuster hopeful would compete with Merck &Co’ s Zostavax. ... By contrast, Zostavax - currently the only shingles vaccine on the market - has an efficacy of between 18% and 70% and is both less

• GSK's blockbuster hopeful Shingrix filed in US

  In contrast, Zostavax' efficacy is generally between 18% and 70% and is known to decline in older people. ... GSK is hoping that increased efficacy means it will be favoured ahead of Zostavax and also drive up vaccination rates against shingles, which